Concordant studies on other cancer entities demonstrated that ERβ expression is decreased or lost in a variety of tumors when compared to normal tissue, a fact that was reported to have negative consequences on survival or therapy of different cancer entities [31–35]. This evidence concerns the gene ESR2 and cancer.